Comparison of Complement Factors and Genetic Polymorphisms of AMD Between Patients With Systemic Lupus Erythematosus (SLE) With and Without Retinal “Pseudo-drusen-like” Deposits: Case-control Study (PL-AMD)

Overview

The rationale of this research is to determine if patients with lupus and presenting retinal "pseudo-drusen-like" deposits have genetic and complement-related similarities with AMD patients. Based on the results obtained, this study could lead to future research that could better target the treatment of patients with lupus or patients with AMD (Age related Macular Degeneration). The primary objective is to check if patients with lupus, treated or not with antimalarial drugs, with "pseudo-drusen-like" deposits have a different complement profile (functional exploration of complement, complement factors, genetic complement polymorphisms involved in AMD) compared to patients without "pseudo-drusen-like" deposits.

Full Title of Study: “Comparison of Complement Factors and Genetic Polymorphisms of AMD Between Patients With Systemic Lupus Erythematosus (SLE) With and Without Retinal “Pseudo-drusen-like” Deposits: Case-control Study (PLAMD)”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: May 15, 2021

Interventions

  • Procedure: Blood test
    • Blood test for complement factors and genetic polymorphisms of AMD analysis

Arms, Groups and Cohorts

  • Case (with pseudo-drusen-like deposits)
    • Patients with lupus, treated or not with antimalarial drugs, with “pseudo-drusen-like” deposits
  • Control (without pseudo-drusen-like deposits)
    • Patients with lupus, treated or not with antimalarial drugs, without “pseudo-drusen-like” deposits

Clinical Trial Outcome Measures

Primary Measures

  • Comparison of AMD genetic polymorphisms between case and control patients
    • Time Frame: Baseline
  • Comparison of complement factors between case and control patients
    • Time Frame: Baseline

Participating in This Clinical Trial

Inclusion Criteria

  • Systemic lupus erythematosus – Case patients : with "pseudo-drusen-like" deposit – Control patients : without "pseudo-drusen-like" deposit Exclusion Criteria:

  • Patient under a measure of legal protection

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 50 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Fondation Ophtalmologique Adolphe de Rothschild
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Martine MAUGET FAYSSE, Principal Investigator, Fondation Ophtalmologique A. de Rothschild

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.